Lutetium Dotatate LU-177

BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- Curium™ is pleased to announce that it has prevailed in the patent dispute brought by Novartis subsidiary Advanced Accelerator Applications against Curium™ concerning Curium’s Lutetium Lu 177 dotatate product. In the court decision issued yesterday by the Delaware U.S. District Court, Justice Noreika adjudicated that all relevant patent claims asserted by Novartis/AAA are invalid and not infringed by Curium™, representing a complete victory for Curium™. This favorable court decision paves the way for Curium’s plans to launch its Lutetium Lu 177 dotatate product in the U.S. and commercialize a therapy for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults across the United States. Renaud Dehareng, Curium’s group chief executive officer, said: “We are pleased with the court’s decision. Curium™ is focused on building a durable theranostics platform that pairs our diagnostic leadership with targeted radioligand therapies — and doing so with the operational discipline required to serve patients reliably at scale.” Michael Patterson, Curium’s North American chief executive officer, said: “This outcome brings Curium a step closer in our mission to deliver what patients, clinicians and health systems need: timely access to critical targeted radiopharmaceuticals. Curium™ has more than 100 years of experience in nuclear medicine and a long-standing commitment of over 30 years to the NET community, supplying diagnostic products that help detect neuroendocrine tumors today and a pipeline of investigational drugs in development.” About Curium Curium™ is an independent global radiopharmaceutical leader driving innovation in nuclear medicine to change patients’ lives. With an industry heritage dating back more than 100 years, Curium™ has proven expertise in the development, manufacturing and supply of radiopharmaceuticals that transform the way cancer is diagnosed and treated. Headquartered in Boston with offices around the world, Curium’s mission is to find new and better ways to diagnose and treat cancer. With a global footprint that extends to more than 70 countries, a skilled and dedicated team of over 3,800 employees, and four manufacturing sites, Curium™ is uniquely qualified to meet the significant supply and distribution of established products that underlie success in the radiopharmaceuticals market. Curium’s global leadership is embodied in a diverse and extensive portfolio of over 45 products that advance patient care. Curium’s pioneering legacy in nuclear medicine is the foundation of the company’s dedication to innovation and portfolio expansion to cancer therapeutics, particularly in neuroendocrine tumors and with a late-stage pipeline exploring opportunities in prostate cancer. To learn more, visit www.curiumpharma.com. Inquiries:Curium GroupCamilla CampellVP, Head of Global CommunicationsCamilla.campbell@curiumpharma.com

The emergence of radiopharmaceuticals represents one of the most significant shifts in modern oncology and diagnostic medicine, potentially moving the field away from blanket treatments toward a highly personalized search and destroy mission at a cellular level. Unlike traditional drugs that may sit on a shelf for months, these are living medical isotopes combined with biological molecules that function as homing beacons, delivering targeted radiation directly to malignant cells while sparing healthy tissue. The very radioactive properties that make them powerful therapies also make them a logistical challenge. In the world of nuclear medicine, radiopharmaceuticals are constantly decaying. For this reason, air transport accounts for a 61.2% share of radiopharmaceutical transport. The moment they are synthesized in a cyclotron or nuclear reactor, a relentless countdown begins. This creates a high-stakes race against the laws of physics, where the therapeutic value of the shipment literally vanishes with every passing hour. Markens mission for nuclear medicine is to deliver these breakthroughs at a targeted time in pristine condition to ensure maximum efficacy. The logistical framework required to move these volatile assets is arguably the most demanding in the entire pharmaceutical sector, characterized by a just-in-time delivery model that leaves absolutely no room for friction. These shipments require high levels of communication and streamlined processes. Beyond the standard rigors of cold-chain management, carriers navigate a complex web of stringent regulatory hurdles, including the Department of Transportation (DOT) Class 7 hazardous materials and international aviation protocols.The transition from general cell and gene therapies to the specific rigors of nuclear medicine highlights a different facet of elevated logistical complexity. While both fields represent the cutting edge of personalized treatment, radiopharmaceuticals introduce the uncompromising element of nuclear physics into the supply chain. Unlike standard regenerative medicines that can often be cryopreserved to pause their biological activity, radioactive isotopes are governed by an immutable physical decay that begins the moment they are synthesized. This creates an environment of extreme time-sensitivity. For radiopharmaceuticals, the logistics is quite literally racing against the atoms themselves. To understand the gravity of this challenge, it takes only a look at the emerging field to see the coordination of several isotopes at once creates a significant logistical puzzle. The transition from traditional, localized medicine to a globally distributed, precision driven model has necessitated a total reimagining of traditional supply chains. While standard pharmaceuticals often benefit from stable shelf lives and forgiving shipping windows, the radiopharmaceutical sector operates under an on-demand reality complicated by the product decay. This shift bridges the gap between the theoretical promise of next generation, personalized therapies and the practical, high-stakes execution required to move active isotopes across continents. To understand the gravity of this challenge, one can simply look at the emergence of new advances.The rise of theranostics, a powerful combination of therapeutics and diagnostics, has further complicated this landscape by integrating two different isotopes into a single patient care plan. This targeted approach typically utilizes a diagnostic isotope, such as gallium-68, to identify tumors via PET scan, followed by a therapeutic isotope like lutetium-177 to deliver the localized radiation. While products like Pluvicto (for prostate cancer) and Lutathera (for neuroendocrine tumors) have revolutionized patient outcomes, they have also doubled the logistical burden. Providers must now synchronize the arrival of two distinct radioactive materials with the patients clinical schedule, ensuring the diagnostics map is created within the timeframe for the therapeutic strike to be administered. The primary difficulty in this supply chain is the half-life of isotopes involved. For example, gallium-68 has a half-life of only about 68 minutes, meaning it loses half of its potency in just over an hour. This narrow window necessitates localized production of the shipment of generators that require specialized handling. Even lutetium-177, which has a more forgiving half-life of roughly 6.7 days, remains highly sensitive to transit times. Any interruption in the white glove delivery service, ranging from heavy traffic to customs holds, can result in the isotope decaying below the required dosage threshold. When the medicine is its own ticking clock, traditional hub-and-spoke distribution models often prove inadequate, requiring dedicated point-to-point couriers instead. Beyond the temporal constraints, the physical requirements for shielding and safety add layers of cost and complexity. Unlike standard biologics, radiopharmaceuticals may require heavy lead or tungsten containers to protect logistics personnel and others from radiation exposure. The weight and dynamics of these containers significantly increase the considerations for each shipment.The value of the packaging also creates a critical return logistics challenge. The expensive, heavy duty transport containers must be tracked, sanitized, and returned to be reused for the next batch. This circular, reverse logistics solution must be managed with the same level of digital visibility as the outbound shipments to avoid bottlenecks anywhere along the supply chain. For patients in remote regions, the distance from a nuclear pharmacy or a major transport hub would typically be a barrier to treatment. The regulatory and infrastructure at international borders also poses a significant challenge to wider accessibility. Every country maintains its own set of rules regarding the transport of Class 7 radioactive materials, and many commercial airlines wont accept radioactive cargo altogether. Markens dedicated experts specializing in Class 7 shipments streamline regulatory compliance and are ready to leverage air and ground resources throughout the UPS network to reach patients worldwide. As the pipeline for nuclear medicine continues to surge, only the pathways built on precision are capable of amplifying growth and carrying the field into the future. '